Corbus Takes On New Cystic Fibrosis Endpoint With Lenabasum
Executive Summary
The US FDA has agreed to Corbus' plan to use pulmonary exacerbations as the only primary endpoint in a new large Phase II study, which is powered to serve as a registrational study.
You may also be interested in...
Finance Watch: CureVac’s IPO Is Ready For Launch
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Finance Watch: Biopharma Stocks See Big Post-IPO Jumps
Public Company Edition: Five out of six drug developers and a CRO have seen their values spike immediately after going public this month. Also, Moderna floats a $500m offering, Revance proposes a $20m note sale, and Nestle invests another $200m in Aimmune.
Aradigm's Linhaliq Suffers 'No' For Reducing Time To Exacerbations At US FDA Panel
Discordant results on Phase III primary endpoint in non-cystic fibrosis bronchiectasis patients troubled advisory committee members, although some suggested they would be more open to approval based upon secondary endpoint data on reduction in exacerbation frequency.